Aberrant expression and association of VEGF and Dll4/Notch pathway molecules under hypoxia in patients with lung cancer
- PMID: 23275310
- DOI: 10.14670/HH-28.277
Aberrant expression and association of VEGF and Dll4/Notch pathway molecules under hypoxia in patients with lung cancer
Abstract
Tumor angiogenesis plays important roles in the pathogenesis and prognosis of lung cancer. Both vascular endothelial growth factor (VEGF) and Dll4/Notch pathways are critical for angiogenesis, whereas their relationship under hypoxia in lung cancer remains unknown. Thus, in the present study, we evaluated the expression of VEGF and Dll4/Notch signaling molecules, and assessed their association with the microvessel density (CD31) and hypoxia (HIF1a) in lung cancer and normal lung tissues using immunohistochemical and Real-time RT-PCR techniques. Then, we investigated the biological function of Dll4 by transfecting Dll4 into HUVECs. In lung cancer tissues, Notch pathway molecules (HES1) and VEGF pathway molecules (VEGFR1 and VEGFR2) were significantly up-regulated, while the ratio of VEGFR1/VEGFR2 was decreased. CD31 and HIF1a were also found to be elevated in lung cancer. VEGFR1 was negatively correlated with Notch1 while positively correlated with Dll4. CD31 was positively correlated with HIF1a but negatively correlated with VEGFR1. Moreover, HIF1a was nearly positively correlated with HES1 in lung cancer tissues. After transfection, Dll4, Notch1 and VEGFR1 were up-regulated while VEGF and VEGFR2 were down-regulated in Dll4-transfected HUVECs compared with controls. Also, our findings suggest that the expression of VEGF and VEGFR2 increased gradually with the disease progression of lung cancer. In summary, VEGF and Notch signaling pathway molecules were overexpressed in lung cancer, which positively correlates with hypoxia (HIF1a) and angiogenesis (CD31). There might be a negative feedback loop between VEGF and Dll4/Notch signaling pathway in lung tumor angiogenesis.
Similar articles
-
Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells.Microvasc Res. 2008 Mar;75(2):144-54. doi: 10.1016/j.mvr.2007.06.006. Epub 2007 Jun 29. Microvasc Res. 2008. PMID: 17692341
-
The vascular delta-like ligand-4 (DLL4)-Notch4 signaling correlates with angiogenesis in primary glioblastoma: an immunohistochemical study.Tumour Biol. 2016 Mar;37(3):3797-805. doi: 10.1007/s13277-015-4202-8. Epub 2015 Oct 15. Tumour Biol. 2016. PMID: 26472724
-
Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch/Dll4 pathway.Carcinogenesis. 2013 Mar;34(3):667-77. doi: 10.1093/carcin/bgs386. Epub 2012 Dec 13. Carcinogenesis. 2013. PMID: 23239744
-
The Notch signaling pathway in head and neck squamous cell carcinoma: A meta-analysis.Adv Clin Exp Med. 2017 Aug;26(5):881-887. doi: 10.17219/acem/64000. Adv Clin Exp Med. 2017. PMID: 29068587 Review.
-
Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications.Front Biosci (Landmark Ed). 2009 Jan 1;14(8):3094-110. doi: 10.2741/3438. Front Biosci (Landmark Ed). 2009. PMID: 19273260 Review.
Cited by
-
[The targets research of non-small cell lung cancer targeted therapy].Zhongguo Fei Ai Za Zhi. 2013 Feb;16(2):107-13. doi: 10.3779/j.issn.1009-3419.2013.02.09. Zhongguo Fei Ai Za Zhi. 2013. PMID: 23425904 Free PMC article. Review. Chinese. No abstract available.
-
Poor outcome in hypoxic endometrial carcinoma is related to vascular density.Br J Cancer. 2019 May;120(11):1037-1044. doi: 10.1038/s41416-019-0461-2. Epub 2019 Apr 23. Br J Cancer. 2019. PMID: 31011231 Free PMC article.
-
Meta-analysis reveals the correlation of Notch signaling with non-small cell lung cancer progression and prognosis.Sci Rep. 2015 May 21;5:10338. doi: 10.1038/srep10338. Sci Rep. 2015. PMID: 25996086 Free PMC article.
-
Role of Delta-Notch signaling in cerebral cavernous malformations.Neurosurg Rev. 2016 Oct;39(4):581-9. doi: 10.1007/s10143-015-0699-y. Epub 2016 Jan 16. Neurosurg Rev. 2016. PMID: 26779617 Review.
-
Current Status and Future Prospects of TROP-2 ADCs in Lung Cancer Treatment.Drug Des Devel Ther. 2024 Nov 6;18:5005-5021. doi: 10.2147/DDDT.S489234. eCollection 2024. Drug Des Devel Ther. 2024. PMID: 39525044 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical